Senior Fellowships in Public Health and Tropical Medicine: people we've funded
This list includes current and past grantholders.
Dr Christophe Antonio-Nkondjio
OCEAC, Yaoundé, Cameroon
Assessment of larviciding efficacy for integrated vector control in the city of Yaoundé, Cameroon
Long-lasting insecticide-treated nets are the main means of malaria prevention in Cameroon, but the rapid evolution of insecticide resistance in main malaria vectors is limiting their efficiency. Complementary approaches are requested to improve the fight against malaria transmission and to restore the efficiency of insecticide-treated nets.
During this study, I will investigate whether adding larviciding for controlling malaria vectors in an urban setting such as the city of Yaoundé, could improve malaria control. After identifying aquatic breeding habitats distribution across drainage systems and beyond, I will assess if regular treatment of these mosquitoes’ habitats with the larvicide vectomax can decrease adult mosquitoes’ densities and malaria transmission. I will also assess if larviciding can reduce the prevalence of pyrethroid resistance in vector populations and if it is a good tool for managing insecticide resistance.
This study will generate a novel and important set of data and knowledge that will be of value for implementing larval control operations in Cameroon and across Africa.
Professor Eugene Kinyanda
Medical Research Council/Uganda Virus Research Institute on Aids, Uganda
Integrating the management of depression into routine HIV care in Uganda (the HIV+D trial)
Most of HIV care in sub-Saharan Africa does not include mental health care despite HIV/AIDS being associated with a heavy burden of mental disorders. This project aims to evaluate a model for the integration of mental health care in public HIV care services in Uganda. The proposed model will be based on the Manas intervention which is a mental health integration model that was successfully evaluated in public primary health care in India (in a non-HIV population). This study will develop and adapt the intervention to HIV care in Uganda and subject the adapted intervention to a clinical trial.
This study will be undertaken among people living with HIV attending HIV care at public health care facilities in the three study districts in central and south-western Uganda. The planned intervention will involve four steps and will be delivered by a team that will include members of the HIV care team at public health facilities and lay health workers, all supported by specialist mental health workers from referral hospitals.
Dr Helen McIlleron
University of Cape Town
Pharmacometrics to advance novel regimens for drug-resistant tuberculosis
For the first time in more than 50 years, there are new drugs to treat tuberculosis (TB), a disease that affects more than 10 million people each year. These new drugs may be particularly important for treatment of drug-resistant TB that doesn’t respond to standard, six-month oral treatment. More than half a million people get this form of TB each year. The treatment available is weak and toxic, it lasts up to two years including about eight months of daily injections and only about half of people who get treated get better.
PandrTB takes advantage of the endTB trial, a trial of new all-oral regimens. In patients who take part in the endTB trial, we will measure how much of each TB drug is in the blood and estimate how much is necessary for successful treatment and how much is present in people who have side effects.
PandrTB will use this information to predict the amount of each drug, and which drugs, patients should receive to have the highest chance of cure and the lowest chance of developing side effects.